^
Association details:
| Biomarker: | Chr t(11;14) |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | bortezomib (Proteasome inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Real-World Outcomes In Myeloma Patients With t(11; 14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database
Published date:
09/10/2023
Excerpt:
CONTRADICTING EVIDENCE: Comparing the t(11;14) vs non-t(11;14) groups, the majority of patients received bortezomib-based treatment in line 1...Compared with non-t(11;14), those with t(11;14) had a shorter PFS in lines 1 and 2.
Source:
Title:
Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma
Published date:
11/04/2021
Excerpt:
This non-interventional, retrospective observational cohort study included patients with t(11;14) MM….A PR or better was observed in 53% of patients with BortDex. The median TTNT for this cohort was 8.4 months and median OS was 46.1 months.
DOI:
https://doi.org/10.1182/blood-2021-149270
Source:
Title:
Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma
Published date:
11/01/2018
Excerpt:
...8 (17%) pts with t(11;14) and 5 (11%) pts with BRAF V600E mutations. Eight (17%) out of the 46 pts were treated in molecularly oriented (MO) personalized therapies or eaCTs, and 38 (83%) pts were treated in non-MO therapies or eaCTs. The MO pts received BRAF inhibitor alone or in combination with MEK inhibitor (n=5), or BCL2 inhibitor given in combination with bortezomib and dexamethasone (n=3). The overall response rate was 75% (4 VGPR, 1 PR and 1 CR) in MO pts versus 11% (4 PR) in non-MO pts (p<0.0001).
Secondary therapy:
Bcl2 inhibitor + BRAF inhibitor;
DOI:
doi.org/10.1182/blood-2018-99-111050
